Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 10/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | CTSK | P43235 | 2/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.56 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.55 |
| ▸ | GLP1R | P43220 | 6/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29606175 | 0.93 | NPBWR1 (0.57) | NPBWR1GLP1R | |
| SCHEMBL29373802 | 0.93 | NPBWR1 (0.57) | NPBWR1GLP1R | |
| SCHEMBL29606879 | 0.93 | NPBWR1 (0.57) | NPBWR1GLP1R | |
| SCHEMBL29412450 | 0.93 | NPBWR1 (0.57) | NPBWR1GLP1R | |
| SCHEMBL30043228 | 0.93 | NPBWR1 (0.57) | NPBWR1GLP1R | |
| SCHEMBL30636834 | 0.93 | NPBWR1 (0.57) | NPBWR1GLP1R | |
| SCHEMBL29350424 | 0.93 | NPBWR1 (0.57) | NPBWR1GLP1R | |
| SCHEMBL29417894 | 0.91 | NPBWR1 (0.59) | NPBWR1CTSBCTSKGLP1R | |
| SCHEMBL29375953 | 0.90 | TLR2 (0.56) | NPBWR1CTSBCTSKMAGI3GLP1R | |
| SCHEMBL29433937 | 0.89 | KISS1R (0.61) | NPBWR1CTSBCTSKKISS1RMAGI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294885-A1 | ENGINEERED ENZYMES AND METHODS OF MAKING AND USING | AGAIN BIO APS (DK) | 2024-09-05 | — | — | US | claimed |
| EP-4423259-A1 | ENGINEERED ENZYMES AND METHODS OF MAKING AND USING | Genomatica, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| WO-2023076966-A1 | ENGINEERED ENZYMES AND METHODS OF MAKING AND USING | GENOMATICA, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| US-20260113699-A1 | SELECTION OF SUBSCRIPTION PROFILES | TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (SE) | 2026-04-23 | — | — | US | disclosed |
| EP-4599610-A1 | SELECTION OF SUBSCRIPTION PROFILES | Telefonaktiebolaget LM Ericsson (publ) (SE) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025062278-A1 | SELECTION OF AN AVAILABLE NETWORK | TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (SE) | 2025-03-27 | — | — | WO | disclosed |
| US-12213977-B2 | Methods and compositions for treating melanoma | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240294885-A1 | ENGINEERED ENZYMES AND METHODS OF MAKING AND USING | AGAIN BIO APS (DK) | 2024-09-05 | — | — | US | disclosed |
| EP-4423259-A1 | ENGINEERED ENZYMES AND METHODS OF MAKING AND USING | Genomatica, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240121708-A1 | SELECTION OF AN AVAILABLE NETWORK | TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (SE) | 2024-04-11 | — | — | US | disclosed |
| WO-2024074897-A1 | SELECTION OF SUBSCRIPTION PROFILES | TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (SE) | 2024-04-11 | — | — | WO | disclosed |
| WO-2023076966-A1 | ENGINEERED ENZYMES AND METHODS OF MAKING AND USING | GENOMATICA, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-11389522-B2 | Flavivirus and alpha virus virus-like particles (VLPS) | TECHNOVAX, INC. (US) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260113699-A1 | SELECTION OF SUBSCRIPTION PROFILES | EIF3I, U2SURP, SLIRP | NPBWR1 4615/4885CTSB 4415/4885CTSK 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.